EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieÄquivalenzstudie

Vonoprazan and amoxicillin dual therapy for 14 days as the first‐line treatment of Helicobacter pylori infection: A non‐inferiority, randomized clinical trial

Yi Hu, Xiang-Hua Huang, Bo Zhou, Meng-Lan Liu, Ye-Fei Liu, Tao Yu, Ping Sun, Bin-Bin Tan, Yang Hu, Fei Cheng, Xiao-Lin Pan, Jun-Bo Hong und 3 weitere

Helicobacter · 2024

DOI: 10.1111/hel.13045 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, 2024. Verfasst von Yi Hu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Ch…. Hauptthemen laut MEDLINE: Helicobacter Infections, Pyrroles, Sulfonamides, Amoxicillin. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China, The First Affiliated Hospital of Nanchang University Clinical Research and Cultivation Project, the Key Research and Development Program of Jiangxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We previously optimized the duration and dose of vonoprazan and amoxicillin dual therapy in China. The efficacy of vonoprazan with b.i.d. amoxicillin in comparison with vonoprazan‐containing quadruple therapy as the first‐line treatment of Helicobacter pylori infection has not been adequately evaluated.

Methods

In a non‐inferiority, randomized clinical trial, H. pylori infected and treatment‐naïve patients were randomly assigned to receive 14 days of either vonoprazan dual (vonoprazan 20 mg and amoxicillin 1 g twice daily) or quadruple therapy (vonoprazan 20 mg + amoxicillin 1 g + furazolidone 100 mg + bismuth potassium citrate 600 mg twice daily). H. pylori status was confirmed using 13 C‐urea breath tests or fecal antigen test. The primary outcome was the H. pylori eradication rate following vonoprazan dual and quadruple therapy at 4–12 weeks. We also compared drug compliance to either regimen and documented their side effect.

Results

A total of 190 subjects were randomized. The eradication rate of vonoprazan dual and quadruple therapy were 87.4% and 92.6% ( p = 0.23) by intention‐to‐treat analysis, respectively, and 96.5% and 97.7% ( p = 0.63) by per‐protocol analysis, respectively. The efficacy of vonoprazan dual therapy was non‐inferior to vonoprazan‐containing quadruple therapy in per‐protocol analysis ( p < 0.001; difference: −1.2%; 90% confidence interval: −5.4% to 3.0%).

Conclusion

Vonoprazan with b.i.d. amoxicillin for 14 days provided similar satisfactory efficacy with vonoprazan‐containing quadruple therapy as a first‐line H. pylori treatment in China.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsPyrrolesSulfonamidesAmoxicillinDrug Therapy, CombinationHelicobacter pyloriAnti-Bacterial AgentsHumansFemaleMiddle AgedMaleAdultTreatment OutcomeChinaAgedProton Pump Inhibitors

Stichwörter der Autor:innen

Helicobacter pyloriamoxicillindual therapyefficacyvonoprazan

Substanzen

Pyrroles1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineSulfonamidesAmoxicillinAnti-Bacterial AgentsProton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Department of Surgery, The Chinese University of Hong Kong, Shatin, China.
  • Department of Gastroenterology, Shenzhen hospital of The First Affiliated Hospital of Nanchang University, Shenzhen, China.

ORCID-Profile: Xu Shu, Yin Zhu, Nong-Hua Lu

Förderung

  • National Natural Science Foundation of China
  • The First Affiliated Hospital of Nanchang University Clinical Research and Cultivation Project
  • the Key Research and Development Program of Jiangxi Province
  • the Project for Academic and Technical Leaders of Major Disciplines in Jiangxi Province

Zitieren

APA

Hu, Y., Huang, X. H., Zhou, B., Liu, M. L., Liu, Y. F., Yu, T., Sun, P., Tan, B. B., Hu, Y., Cheng, F., Pan, X. L., Hong, J. B., Shu, X., Zhu, Y., & Lu, N. H. (2024). Vonoprazan and amoxicillin dual therapy for 14 days as the first‐line treatment of Helicobacter pylori infection: A non‐inferiority, randomized clinical trial. Helicobacter. https://doi.org/10.1111/hel.13045

Vancouver

Hu Y, Huang XH, Zhou B, Liu ML, Liu YF, Yu T, et al. Vonoprazan and amoxicillin dual therapy for 14 days as the first‐line treatment of Helicobacter pylori infection: A non‐inferiority, randomized clinical trial. Helicobacter. 2024. doi:10.1111/hel.13045

BibTeX
@article{Hu2024,
  author = {Hu, Yi and Huang, Xiang-Hua and Zhou, Bo and Liu, Meng-Lan and Liu, Ye-Fei and Yu, Tao and Sun, Ping and Tan, Bin-Bin and Hu, Yang and Cheng, Fei and Pan, Xiao-Lin and Hong, Jun-Bo and Shu, Xu and Zhu, Yin and Lu, Nong-Hua},
  title = {Vonoprazan and amoxicillin dual therapy for 14 days as the first‐line treatment of Helicobacter pylori infection: A non‐inferiority, randomized clinical trial},
  journal = {Helicobacter},
  year = {2024},
  doi = {10.1111/hel.13045}
}
Kostenlos starten →